“…we’re 2 and a half years out from potential launch.”

The short answer: in its Viking Therapeutics Q3 2026 report on October 28, 2026, Viking said both Phase 3 trials of its weekly weight-loss shot, VK2735, are fully enrolled and should finish in 2027. It also started Phase 3 trials of a daily VK2735 pill and ended September with about $960 million in cash.

What it didn’t say is just as useful: there’s no new efficacy data, no results date beyond 2027, and the CEO put a possible launch about two and a half years away. If you’re waiting for VK2735, our reading is that means roughly 2029.

Two panels. Left: in Viking's VK2735 maintenance study, people switched from weekly shots to every-other-week doses kept 83%, 90% and 97% of their week-21 weight loss at week 33 (5, 7.5 and 10 mg), monthly doses kept 85% (range 82 to 90%), and placebo kept 61%. Right: Viking's timeline, from VK3019 dose study ending late 2026, to VANQUISH trials completing in 2027, extension results in 2028 and a potential launch about 2029 by our reading of the CEO's remark
Less frequent doses held most of the weight off in a small, early study. The big trials still have to finish.

In this post you’ll learn what Viking reported for Q3 2026, where the VANQUISH and SUNRISE trials stand, what the monthly-dose data does and doesn’t show, and when VK2735 might realistically reach a pharmacy. About 6 minutes.

What Was in the Viking Therapeutics Q3 2026 Report?

Viking has no drug on sale, so it reported no revenue. It lost $183.2 million in the quarter, about double the $90.8 million it lost a year earlier. That’s per its October 28, 2026 results release, filed with the SEC.

  • Research spending: $166.8 million, up from $90.0 million, mostly from running big trials and making the drug.
  • Overhead: $20.3 million, up from $8.6 million.
  • Cash: about $960 million in cash and short-term investments on September 30, up from $706 million at the end of 2025.
  • New money: a September sale of stock and convertible notes raised about $575 million before costs, or about $550 million after.

On the call, finance chief Greg Zante said he expects Viking to use about $100 million a quarter on average. By our math, that’s roughly two years of cash at today’s pace, and spending usually climbs as a launch gets close.

Action item: Read a drug developer’s earnings as a trial update, not a health update. The money mostly tells you whether the trials can finish.

Where Do the VANQUISH Trials Stand?

Both Phase 3 trials of the weekly VK2735 shot are fully enrolled. Viking expects both to finish in 2027. Lian said on the call that both kept moving toward completion during the third quarter.

  • VANQUISH-1 (obesity, no type 2 diabetes): about 4,500 people, enrolled in about five months.
  • VANQUISH-2 (obesity plus type 2 diabetes): about 1,000 people, enrolled in about nine months.
  • Design: weekly 7.5 mg, 12.5 mg or 17.5 mg versus placebo for 78 weeks. The main result is percent weight change versus placebo.
  • Extensions: up to 52 more weeks, starting in early 2027 and testing every-other-week and monthly doses in VANQUISH-1. Results are expected in 2028.

Lian also said the share of people dropping out, which is still blinded, is in line with what Viking planned for. He gave no number. Asked to predict the 78-week weight loss, he declined.

VK2735 acts on the same two gut-hormone receptors as tirzepatide (Zepbound and Mounjaro): GLP-1 and GIP. That’s why analysts kept asking how it stacks up. Lian warned against comparing results across different trials.

Action item: When you see a VK2735 headline in 2027, check two things first: which trial it’s from, and whether it counts everyone who started or only people who stayed on the drug.

What Is the SUNRISE Trial for the VK2735 Pill?

SUNRISE is Viking’s Phase 3 program for a once-a-day VK2735 tablet. It started in October 2026, with two trials of 560 adults each. SUNRISE-1 is for people with obesity or overweight without type 2 diabetes; SUNRISE-2 is for people with type 2 diabetes, per RTTNews.

People take 27.5 mg, 35 mg or 55 mg daily, or placebo, for 68 weeks. Viking hasn’t said when results are due.

In Phase 2, the tablet cut weight by up to 12.2% in 13 weeks at the highest dose, or 10.9% after subtracting placebo. That counts only people who were dosed and had weights recorded, not everyone who started.

And side effects were real: 20% of people on the tablet stopped because of them, versus 13% on placebo, per Viking’s August 2025 release.

Phase 3 tops out at 55 mg, below the 120 mg dose behind that 12.2%. Lian said the choice weighed tablet size, how many tablets people take, and cost to make. If approved, he said it would be the first approved pill that hits both GLP-1 and GIP.

Action item: If you want a pill now, the approved options are Lilly’s Foundayo and Novo Nordisk’s Wegovy pill. Our Foundayo vs Zepbound guide compares the pill and the shot.

Could You Take VK2735 Once a Month?

Maybe, someday. In a small Viking study, people who switched from weekly shots to every-other-week shots kept 90% of the weight they’d lost, and monthly shots kept 85%, versus 61% on placebo. That’s from Viking’s September 22, 2026 release.

Here’s how it worked. About 180 people took weekly VK2735 for 21 weeks and lost about 16% to 19% of their weight. Then they switched to a less frequent dose (usually lower), or to placebo, for 12 weeks. Like the pill data, these results count people who were dosed and weighed, not everyone who started.

  • Every other week (5, 7.5 or 10 mg): kept 83%, 90% and 97% of their week-21 loss.
  • Once a month (five dose groups, 10 to 22.5 mg): kept 82% to 90%.
  • Stomach side effects during maintenance were about the same as on placebo, Viking said.

I think this is the most interesting thing Viking has. Fewer shots could mean lower cost and an easier routine for life. But 12 weeks is short, the groups were small, and none of it is peer reviewed. Part 2, with about 195 people and pill and shot options, reports in 2027, per the Q3 release.

Action item: If you’re on Zepbound or Wegovy, don’t stretch your doses to copy this. That’s a different drug in a small study; any change to your schedule is your prescriber’s call.

What About Viking’s Amylin Drug, VK3019?

VK3019 is an early-stage amylin drug, like eloralintide and cagrilintide. Its first study in people should finish by the end of 2026, with a multiple-dose study planned for early 2027. That’s per the Q3 release and the call.

Lian said VK3019 might be paired with VK2735 or used alone by people who can’t tolerate GLP-1 drugs. It’s years behind Lilly’s and Novo’s amylin drugs, which we cover in Cagrilintide vs Eloralintide.

Action item: File VK3019 under “watch, don’t wait.” A first-in-human study tells you about safety and dosing, not how much weight people will lose.

When Will VK2735 Be Available?

Probably not before about 2029, by our reading of what Viking’s CEO said. The shot trials finish in 2027, then Viking would need to file and wait for an FDA review. Lian put a potential launch about two and a half years away; 2029 is our reading of that.

Whether the extension data goes into the first FDA filing is still undecided; Lian said a later add-on filing is more likely. Either way, nothing about VK2735 is for sale legally today.

That’s a long wait in a crowded race. Lilly plans to file retatrutide in early 2027, and Novo has already asked the FDA to approve CagriSema, which pairs an amylin drug with semaglutide. We track those in Retatrutide vs EloraTZP and When Will Retatrutide Be Available?

Action item: Don’t buy “VK2735” online. The FDA has warned about unapproved GLP-1 drugs sold for weight loss, including ones labeled “for research purposes.”

What We Don’t Know Yet

The quarter answered “is it on track?” and little else. As of October 30, 2026:

  • How much weight people lose over 78 weeks. Viking declined to project a number.
  • How many people quit. Viking says the blinded dropout rate is as expected but gave no figure.
  • When SUNRISE reports. No date was given for the pill trials.
  • What a year of VK2735 costs. No company has set a price for a drug that isn’t approved yet.
Action item: Treat any VK2735 “results” you see before 2027 with suspicion unless they come from Viking, a journal or a medical meeting.

Quick Answers

What was in the Viking Therapeutics Q3 2026 report? A net loss of $183.2 million, no revenue and about $960 million in cash on September 30, 2026. Both VANQUISH trials are fully enrolled and due to finish in 2027.

Is VK2735 approved? No. It’s in Phase 3 as a weekly shot and a daily pill, and isn’t approved anywhere.

When will VK2735 results come out? Viking expects the VANQUISH shot trials to finish in 2027 and gave no exact readout date. Extension results are expected in 2028.

Can VK2735 be taken monthly? In a small 12-week maintenance study, monthly doses kept 82% to 90% of earlier weight loss, versus 61% on placebo. It’s early, unpublished data.

Is VK2735 the same as Zepbound? No. Both target GLP-1 and GIP, but they’re different molecules from different companies, and no trial has compared them directly.

What This Means for You

✅ You know VK2735’s shot trials are full and should finish in 2027

✅ You know a VK2735 pill started Phase 3 in October 2026

✅ You know what the monthly-dose data shows, and how early it is

✅ You know the CEO put a launch about two and a half years away

✅ You know not to buy VK2735 online

The 5-Minute Version (Screenshot This)

  1. News: Viking reported Q3 2026 results and held its call on October 28, 2026.
  2. Money: no revenue, $183.2 million net loss, about $960 million in cash after a $575 million raise.
  3. Shot (VANQUISH): about 5,500 people enrolled across two trials; both due to finish in 2027.
  4. Pill (SUNRISE): two 68-week Phase 3 trials of 560 people each started in October 2026.
  5. Timing: the CEO put a potential launch about two and a half years out.

Conclusion

The Viking Therapeutics Q3 2026 update was a progress report, not a breakthrough. The trials are full, the bank account is deep, and the most intriguing idea, a shot you might take once a month, rests on one small study. For anyone hoping VK2735 is the next thing their doctor can prescribe, the honest answer is: not soon.

Your one action today: if cost or side effects are what keep you off treatment, ask your prescriber about the options approved now instead of waiting years for VK2735.

So tell me: would a once-a-month shot change whether you’d stay on a weight-loss drug long term?

Sources